CMS to work close­ly with FDA on ac­cel­er­at­ed ap­proval pay­ment re­forms

The FDA has his­tor­i­cal­ly not dealt with drug pric­ing, un­less it’s re­lat­ed to sav­ings from gener­ic drug com­pe­ti­tion.

But that’s slow­ly chang­ing now, with CMS say­ing it will work close­ly with the US drug reg­u­la­tor on both a new pi­lot project to try to save the fed­er­al gov­ern­ment on ac­cel­er­at­ed ap­proval drugs, and on im­ple­ment­ing the In­fla­tion Re­duc­tion Act, which will es­tab­lish new gov­ern­ment price ne­go­ti­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER